JAK Inhibitors for Alopecia Areata: 2022 Research Summary
This is a plain-language summary of the original published research. We do not add conclusions or opinions of our own. This is not medical advice — consult a certified healthcare practitioner before making any decision.
Original research published in Frontiers in Pharmacology, 2022
JAK Inhibitors for Alopecia Areata: 2022 Research Summary
Study conclusion
JAK inhibitors treat alopecia areata (immune-related patchy hair loss) — NOT androgenetic alopecia (pattern baldness). This study combined results from 14 prospective studies involving 1,845 patients with alopecia areata. Oral JAK inhibitors significantly outperformed controls. Topical JAK inhibitors showed no significant benefit. High recurrence rates were seen after stopping treatment.
Strength of evidence
Who it applies to
Who was studied
Adults with alopecia areata (immune-related patchy hair loss). 1,845 patients across 14 prospective studies, including 5 randomised controlled trials. Oral JAK inhibitors: baricitinib, ritlecitinib, deuruxolitinib. Topical JAK inhibitors: ruxolitinib cream and others.
Who was NOT studied
People with androgenetic alopecia (pattern baldness). People with alopecia totalis or alopecia universalis. Children.
What to look for when shopping
JAK inhibitors are prescription-only medications. Baricitinib (Olumiant) and ritlecitinib (Litfulo) are FDA-approved for severe alopecia areata. They are not used for pattern baldness. These are specialist medications managed by dermatologists.
What research cannot help you decide
Which specific JAK inhibitor is best for your situation — baricitinib, ritlecitinib, and deuruxolitinib each have different efficacy and safety profiles. What happens if treatment is stopped. These decisions require a specialist dermatologist.
Key findings
- Oral JAK inhibitors significantly outperformed controls for good response rate in alopecia areata (about 6.86 times more likely to achieve good response)
- Topical JAK inhibitors showed no significant benefit compared to controls in this analysis
- Hair loss typically recurs after stopping oral JAK inhibitor treatment
- Baricitinib and ritlecitinib are FDA-approved for severe alopecia areata
- JAK inhibitors treat alopecia areata only — they are NOT used for pattern baldness (androgenetic alopecia)
What this study does not show
- 1.Whether JAK inhibitors work for androgenetic alopecia (pattern baldness). They do not — these are different conditions.
- 2.Which oral JAK inhibitor is most effective. A separate network meta-analysis suggests deuruxolitinib may be superior, but evidence is evolving.
- 3.How long treatment must continue to maintain results. Recurrence after stopping is well-documented.
- 4.Long-term safety of JAK inhibitors. These medications carry risks including infection, thrombosis, and malignancy that require monitoring.
Limitations
- 1.This evidence applies to alopecia areata only — not pattern baldness.
- 2.Topical JAK inhibitors showed no significant benefit in this analysis.
- 3.High recurrence rates mean these treatments require long-term or indefinite use to maintain results.
- 4.JAK inhibitors carry serious safety risks (infections, blood clots, certain cancers) requiring specialist supervision.
- 5.Only 5 of the 14 included studies were randomised controlled trials — 9 were non-randomised prospective studies.
Used in these articles
Links added as fact-checks and articles citing this study are published.